Oncoinvent ASA's Total Assets for the quarter that ended in Dec. 2025 was $20.28 Mil.
During the past 12 months, Oncoinvent ASA's average Total Assets Growth Rate was -20.60% per year.
During the past 3 years, the average Total Assets Growth Rate was 25.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 19.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 10.20% per year.
During the past 11 years, Oncoinvent ASA's highest 3-Year average Total Assets Growth Rate was 40.40%. The lowest was -9.30%. And the median was 7.95%.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Oncoinvent ASA's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Oncoinvent ASA Total Assets Related Terms
Oncoinvent ASA Total Assets Historical Data
* Premium members only.
The historical data trend for Oncoinvent ASA's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Oncoinvent ASA's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoinvent ASA (BRRGF) has a Total Assets of $20.28 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Oncoinvent ASA and its competitors.
Is Oncoinvent ASA's Total Assets too high?
Oncoinvent ASA's current Total Assets is $20.28 Mil. Overall, Oncoinvent ASA has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Total Assets compare to VRTX and REGN?
Oncoinvent ASA's Total Assets of $20.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Oncoinvent ASA and its competitors. Oncoinvent ASA's current Total Assets is $20.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (BRRGF) has a current Total Assets of $20.28 Mil. The stock's GF Value™ is $1,788.00, compared to a current price of $97.09 — trading 94.6% below its estimated fair value. The current Total Assets is $20.28 Mil. Oncoinvent ASA's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Oncoinvent ASA (BRRGF), the current Total Assets is $20.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoinvent ASA (BRRGF) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued.
The current stock price of $97.09 is trading 94.6% below its estimated GF Value™ of $1,788.00.
Key valuation signals for BRRGF:
Total Assets: $20.28 Mil
GF Value™: $1,788.00 vs. price of $97.09 (94.6% below fair value)
No single metric tells the full story. See the BRRGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score
Get the complete analysis for BRRGF
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRRGF has been successfully added to your 
